ストックスクリーナーアプリを入手
0.1472
4.17%
-0.0064
アフターアワーズ：
.14
-0.0072
-4.89%
前日終値:
$0.1536
開ける：
$0.16
24時間の取引高:
3.67M
Relative Volume:
4.87
時価総額：
$10.04M
収益：
$202.00K
当期純損益:
$-28.96M
株価収益率:
-0.2453
EPS:
-0.6
ネットキャッシュフロー:
$-21.85M
1週間 パフォーマンス:
-27.09%
1か月 パフォーマンス:
-36.93%
6か月 パフォーマンス:
-53.39%
1年 パフォーマンス:
-66.16%
1日の値動き範囲:
$0.1337
$0.16
1週間の範囲:
$0.131
$0.1996
52週間の値動き範囲:
$0.131
$0.62
AIM ImmunoTech Inc Stock (AIM) Company Profile
AIM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.1472 | 10.04M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
AIM ImmunoTech Inc (AIM) 最新ニュース
AIM ImmunoTech advances Ampligen for avian influenza vaccine - MSN
AIM ImmunoTech announces follow-up clinical study of Ampligen with FluMist - TipRanks
AIM ImmunoTech announces a planned follow-up clinical study - GlobeNewswire
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks - The Manila Times
4X Immune Response: AIM's Ampligen Breakthrough with AstraZeneca's FluMist Against Bird Flu - StockTitan
AIM ImmunoTech Inc (AIM) Has Recovered -14.29% From Its Low: Is This The Beginning Of A Trend? - Stocks Register
Stocks of AIM ImmunoTech Inc (AIM) are poised to climb above their peers - SETE News
Erasmus Medical Center Safety Committee Grants Approval to - GlobeNewswire
AIM ImmunoTech announces Safety Committee approval to proceed with Phase 2 - TipRanks
Investing in AIM ImmunoTech Inc (AIM) might be a great opportunity, but the stock is a bit undervalued - US Post News
Breakthrough in Pancreatic Cancer Treatment: Clinical Trial Shows 15-Month Disease Stability - StockTitan
Daily Progress: AIM ImmunoTech Inc (AIM) Drop -8.07, Closing at 0.19 - The Dwinnex
AIM’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
AIM ImmunoTech (NYSE:AIM) Stock Price Down 8.1% – What’s Next? - Defense World
AIM ImmunoTech Provides Business Update for the Third Quarter of 2019 - ACCESS Newswire
AIM ImmunoTech files to sell units, no amount given - MSN
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions - Marketscreener.com
AIM ImmunoTech Announces Publication of Final Clinical - GlobeNewswire
AIM ImmunoTech's Ampligen Shows Breakthrough Results in Long COVID Fatigue Treatment Trial - StockTitan
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS - GlobeNewswire
Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance
AIM ImmunoTech's Ampligen Shows Breakthrough Results for Long COVID and ME/CFS Treatment - StockTitan
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
Allegion Plc (ALLE-N) QuotePress Release - The Globe and Mail
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones - GlobeNewswire
AIM ImmunoTech Advances Ampligen Cancer Programs, Reports Strong Clinical Progress Across Pipeline - StockTitan
Mesoblast (NASDAQ:MESO) versus AIM ImmunoTech (NYSE:AIM) Head-To-Head Contrast - Defense World
Analyzing Mesoblast (NASDAQ:MESO) & AIM ImmunoTech (NYSE:AIM) - Defense World
Financial Survey: AIM ImmunoTech (NYSE:AIM) and INmune Bio (NASDAQ:INMB) - Defense World
AIM ImmunoTech shareholders elect new directors amid proxy battle By Investing.com - Investing.com South Africa
AIM ImmunoTech shareholders elect new directors amid proxy battle - Investing.com
Aim Immunotech director William Mitchell sells $883 in stock - Investing.com India
Aim Immunotech director William Mitchell sells $883 in stock By Investing.com - Investing.com Australia
Declaration of Voting Results by AIM ImmunoTech - Marketscreener.com
Ted Kellner low-key on joining pharma firm board he fought to join - The Business Journals
Aim Immunotech CEO Thomas K Equels acquires $4,681 in common stock - Investing.com Canada
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - The Manila Times
AIM ImmunoTech Announces Notification of Noncompliance with - GlobeNewswire
AIM ImmunoTech Faces NYSE American Listing Crisis After 5 Years of Losses - StockTitan
Pharma company proxy fight ends in mixed results for Ted Kellner - The Business Journals
AIM ImmunoTech Strengthens Board Leadership, Advances Cancer Drug Development Strategy - StockTitan
Ted Kellner's multimillion-dollar fight to unseat pharma firm's board - The Business Journals
AIM ImmunoTech Issues an Open Letter to Shareholders - Marketscreener.com
Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board - GlobeNewswire Inc.
UPDATE: Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card - The Manila Times
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card - The Manila Times
AIM ImmunoTech gains Netherlands patent for post-Covid fatigue therapy - Yahoo Finance
AIM ImmunoTech secures patent for post-Covid fatigue therapy - Pharmaceutical Technology
AIM ImmunoTech Inc Provides Information to the Shareholders - Marketscreener.com
AIM ImmunoTech Inc (AIM) 財務データ
収益
当期純利益
現金流量
EPS
AIM ImmunoTech Inc (AIM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MITCHELL WILLIAM M | Director |
Dec 19 '24 |
Sale |
0.19 |
4,580 |
884 |
118,549 |
| Equels Thomas K | CEO & President |
Dec 18 '24 |
Buy |
0.21 |
22,727 |
4,682 |
1,680,695 |
| APPELROUTH STEWART | Director |
Dec 02 '24 |
Buy |
0.21 |
11,112 |
2,356 |
355,509 |
| Equels Thomas K | CEO & President |
Nov 20 '24 |
Buy |
0.20 |
85,000 |
16,915 |
1,637,968 |
| APPELROUTH STEWART | Director |
Nov 20 '24 |
Buy |
0.19 |
81,953 |
15,817 |
321,752 |
| Equels Thomas K | CEO & President |
Nov 20 '24 |
Buy |
0.18 |
60,110 |
11,000 |
1,552,968 |
| Equels Thomas K | CEO & President |
Sep 16 '24 |
Buy |
0.30 |
5,000 |
1,515 |
1,493,042 |
| Equels Thomas K | CEO & President |
Sep 13 '24 |
Buy |
0.31 |
20,000 |
6,160 |
1,488,042 |
| Equels Thomas K | CEO & President |
May 06 '24 |
Buy |
0.41 |
61,729 |
25,000 |
778,184 |
| Rodino Peter W III | COO, Secretary, Gen. Counsel |
May 06 '24 |
Buy |
0.41 |
30,865 |
12,500 |
212,583 |
1.09%
大文字化:
|
ボリューム (24 時間):